2269 • HKG
WuXi Biologics (Cayman) Inc
$71.70
Jun 30, 12:05:00 PM GMT+8 · HKD · HKG · Disclaimer
StockHK listed securityCN headquartered
Previous close
$72.65
Day range
$70.65 - $72.65
Year range
$40.30 - $148.00
Market cap
302.52B HKD
Avg Volume
25.09M
P/E ratio
79.77
Dividend yield
-
Primary exchange
HKG
Market news
Financials
Income Statement
Financial performance
Revenue
Net income
(CNY)Dec 2021Y/Y change
Revenue
2.94B60.38%
Operating expense
492.67M64.83%
Net income
773.17M62.30%
Earnings per share
EBITDA
848.61M37.88%
Effective tax rate
15.97%
Financial performance
Total assets
Total liabilities
(CNY)Dec 2021Y/Y change
Cash and short-term investments
11.13B31.20%
Total assets
44.03B52.03%
Total liabilities
11.33B40.45%
Total equity
32.71B
Shares outstanding
4.22B
Price to book
9.51
Return on assets
4.34%
Return on capital
5.17%
Financial performance
Net change in cash
(CNY)Dec 2021Y/Y change
Net income
773.17M62.30%
Cash from operations
1.32B81.52%
Cash from investing
-930.13M41.60%
Cash from financing
-1.50B-154.45%
Net change in cash
-1.14B-167.30%
Free cash flow
-447.27M58.37%
About
WuXi Biologics is a Chinese headquartered CDMO that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics’ roots date back to 2010 when it was established as a business unit of WuXi AppTec, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. Since then, WuXi Biologics has focused on establishing state-of-the-art research and manufacturing facilities and building partnerships with pharmaceutical and biotech companies in the space. WuXi Biologics ultimately spun out of WuXi AppTec in 2015, and two years later went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites around the world including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore with a planned total production capacity of 220,000 by 2022 and over 430,000 liters by 2023. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. Wikipedia
Founded
2015
Headquarters
Employees
9,864
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for